Nayak Debadatta, Kaur Lovepreet, Bhalerao Rupali, Nahar Karanpreet, Ram Hanuman, Sharma Pawan, Gupta Ankit, Singh Smita, Khurana Anil, Manchanda Raj Kumar
Department of Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, India.
Ayurswasthya Yojana, Central Sector Scheme, Ministry of Ayush, New Delhi, India.
Homeopathy. 2025 Aug;114(3):163-172. doi: 10.1055/s-0044-1788663. Epub 2024 Oct 24.
The study was undertaken to evaluate the protective effect of (EP) 30C on the incidence of dengue fever.
This study was designed as a prospective, open label, parallel cohort study.
Participants were enrolled in two medicine cohort (MC) communities and one control cohort (CC) community. Participants in MC who were more than 5 years of age received four medicated globules and those aged between 1 and 5 years received two medicated globules of EP 30C once a week for 10 weeks. Participants in CC received no medical intervention. Both cohorts received information and educational material regarding dengue.
The primary outcome was incidence of dengue cases based on laboratory confirmation or the clinical definition of dengue as per the case definition notified by the National Vector-Borne Disease Control Program, Government of India, during the 14 weeks of intervention and observation.
The analysis included 20,607 participants residing in three slums of Delhi, of which MC and CC included 15,298 and 5,309 participants respectively. The overall protective effect of EP 30C in MC against probable/laboratory-confirmed dengue was 59.59% (95% confidence interval [CI], 50.74 to 66.85, = 0.0001). The overall protective effect of EP 30C against laboratory-confirmed dengue was 72.78% (95% CI, 54.45 to 83.74, = 0.0001): 26 cases per 15,298 (0.13 per 1,000 person-weeks) in MC versus 33 cases per 5,309 (0.46 per 1,000 person-weeks) in CC.
The use of EP 30C was associated with some protection against probable and laboratory-confirmed dengue.
开展本研究以评估30C 倍半乳糖醛酸酶（EP）对登革热发病率的保护作用。
本研究设计为一项前瞻性、开放标签、平行队列研究。
参与者被纳入两个药物队列（MC）社区和一个对照队列（CC）社区。MC中5岁以上的参与者每周服用四颗药球，1至5岁的参与者每周服用两颗EP 30C药球，持续10周。CC中的参与者未接受医学干预。两个队列均收到了有关登革热的信息和教育材料。
主要观察指标是在14周的干预和观察期间，根据实验室确诊或印度政府国家媒介传播疾病控制计划通报的病例定义中登革热的临床定义得出的登革热病例发病率。
分析纳入了居住在德里三个贫民窟的20607名参与者，其中MC和CC分别包括15298名和5309名参与者。EP 30C在MC中对可能的/实验室确诊的登革热的总体保护作用为59.59%（95%置信区间[CI]，50.74至66.85，P = 0.0001）。EP 30C对实验室确诊的登革热的总体保护作用为72.78%（95%CI，54.45至83.74，P = 0.0001）：MC中每15298人中有26例（每1000人周0.13例），而CC中每5309人中有33例（每1000人周0.46例）。
使用EP 30C与对可能的和实验室确诊的登革热有一定保护作用相关。
